Spondyloarthritis & psoriatic arthritis
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study
Main finding · Secukinumab retention rateResult — go to the resultHazard ratio 1.19 CI 1.02–1.39Authors' conclusion
The better secukinumab retention rate remotely from its launch is explained by its use at an earlier stage of the disease, suggesting a change in the behaviour of prescribing physicians.
Study context
- Population
- Patients with axSpA treated with secukinumab, 50 French centres50 centres
- Participants
- 758 vs 906
- Exposure
- Secukinumab initiated 1 September 2018–13 November 2020 (C2) vs 16 August 2016–31 August 2018 (C1)
- C2n = 758
- C1n = 906reference
- Outcome
- Retention rate of secukinumab
- Follow-up
- 1 year
Methodological detailsmulticentre
- Multicentre
Main finding
Secukinumab retention rate
Hazard ratio
1.19
CI 1.02–1.39
P = 0.0297
By group
C2vs C1
HR 1.19 (CI 1.02–1.39); P = 0.0297
As reported in the abstract
Observational data: associations, not effects.
Further findings
Predictors of 1-year retention (multivariate Cox)
- Line of biologic therapy was the single predictive factor in both cohorts, with better retention when prescribed as first-line biologic
Original publication
Impact of the time of initiation and line of biologic therapy on the retention rate of secukinumab in axial spondyloarthritis (axSpA): data from the French multicentre retrospective FORSYA study. RMD Open. Published 29 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →